These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 10753825)

  • 1. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells.
    Arpinati M; Green CL; Heimfeld S; Heuser JE; Anasetti C
    Blood; 2000 Apr; 95(8):2484-90. PubMed ID: 10753825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells.
    Klangsinsirikul P; Russell NH
    Exp Hematol; 2002 May; 30(5):495-501. PubMed ID: 12031657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.
    MacDonald KP; Rowe V; Filippich C; Thomas R; Clouston AD; Welply JK; Hart DN; Ferrara JL; Hill GR
    Blood; 2003 Mar; 101(5):2033-42. PubMed ID: 12393418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions.
    Huang XJ; Chang YJ; Zhao XY
    Transpl Immunol; 2007 Apr; 17(3):193-7. PubMed ID: 17331846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte colony-stimulating factor produces a decrease in IFNgamma and increase in IL-4 when administrated to healthy donors.
    Rodríguez-Cortés O; Vela-Ojeda J; López-Santiago R; Montiel-Cervantes L; Reyes-Maldonado E; Estrada-García I; Moreno-Lafont MC
    J Clin Apher; 2010; 25(4):181-7. PubMed ID: 20818712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
    Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL
    Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants.
    Volpi I; Perruccio K; Tosti A; Capanni M; Ruggeri L; Posati S; Aversa F; Tabilio A; Romani L; Martelli MF; Velardi A
    Blood; 2001 Apr; 97(8):2514-21. PubMed ID: 11290617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease.
    Pan L; Delmonte J; Jalonen CK; Ferrara JL
    Blood; 1995 Dec; 86(12):4422-9. PubMed ID: 8541530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
    Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):460-7. PubMed ID: 23201472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics.
    Porta MD; Rigolin GM; Alessandrino EP; Maiocchi M; Malcovati L; Vanelli L; Baratè C; Rumi E; Ciccone M; Cuneo A; Lazzarino M; Castoldi G
    Eur J Haematol; 2004 Jan; 72(1):18-25. PubMed ID: 14962258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
    Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
    Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells.
    Morton J; Hutchins C; Durrant S
    Blood; 2001 Dec; 98(12):3186-91. PubMed ID: 11719353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
    Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient.
    Reddy V; Hill GR; Pan L; Gerbitz A; Teshima T; Brinson Y; Ferrara JL
    Transplantation; 2000 Feb; 69(4):691-3. PubMed ID: 10708136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity.
    Baumeister SH; Hölig K; Bornhäuser M; Meurer M; Rieber EP; Schäkel K
    Blood; 2007 Oct; 110(8):3078-81. PubMed ID: 17616642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor.
    Ferrari S; Rovati B; Porta C; Alessandrino PE; Bertolini A; Collovà E; Riccardi A; Danova M
    Cancer Immunol Immunother; 2003 Jun; 52(6):359-66. PubMed ID: 12664135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J; Zhao XY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
    Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L; Blum W; Klisovic R; Penza S; Efebera Y; Hofmeister C; Benson DM; Muthusamy N; Lozanski G; Devine SM
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):658-668. PubMed ID: 26743340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of rhG-CSF mobilization on immunological properties of grafts from peripheral blood and bone marrow].
    Zhao XY; Chang YJ; Huang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):787-90. PubMed ID: 16928322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.